A high PTHrP (parathyroid hormone–related peptide) most often signals humoral hypercalcemia of malignancy: certain tumors (e.g., breast, lung, squamous cell cancers) secrete PTHrP, which mimics PTH to raise blood calcium by increasing bone resorption and renal calcium retention. It usually occurs with low PTH and causes symptoms like weakness, nausea, confusion, polyuria. Treatment targets the cancer and lowers calcium (fluids, bisphosphonates, calcitonin).

PTHrP (parathyroid hormone–related protein) is not a general tumor marker for cancer screening, but it is clinically useful: many solid tumors secrete PTHrP and cause humoral hypercalcemia of malignancy. Measuring PTHrP can help confirm malignancy‑related hypercalcemia and guide management, though it has limited sensitivity and specificity and is not routinely used for cancer surveillance.

Key parathyroid-related peptides include parathyroid hormone (PTH) and parathyroid hormone–related peptide (PTHrP). Therapeutic agents are teriparatide (recombinant PTH 1–34), full‑length PTH 1–84, and abaloparatide (a PTHrP analog). These peptides mimic PTH actions—raising blood calcium, increasing renal calcium reabsorption and bone remodeling—and are used mainly for osteoporosis and some hypoparathyroidism cases under medical supervision.

Parathyroid hormone (PTH) is an endocrine hormone from the parathyroid glands that maintains blood calcium by acting on bone, kidney and vitamin D activation. Parathyroid hormone–related peptide (PTHrP) is produced in many tissues for local paracrine/autocrine roles in development and cell growth; it binds the same receptor and can mimic PTH (eg in malignancy) but isn’t chiefly regulated by serum calcium.

A PTHrP (parathyroid hormone–related peptide) test typically costs about $100–$300 in the United States, can be free on national health services or £40–£150 privately in the UK, and roughly ₹800–₹2,500 in India. Prices vary by laboratory, hospital vs outpatient setting, and whether insurance or public health coverage applies; confirm with your chosen lab or insurer for an exact quote.

Elevated PTHrP (humoral hypercalcemia of malignancy) is most commonly and frequently seen with squamous cell carcinomas—especially lung, head and neck, and esophageal—plus breast cancer. Other tumors that often secrete PTHrP include renal cell, ovarian, endometrial and bladder cancers; some leukemias/lymphomas and other solid tumors can occasionally produce PTHrP, often causing hypercalcemia.